Study Suggests Higher Risk of CV Events When Initiating Denosumab for Osteoporosis in Dialysis Patients

An observational study emulated a target trial to determine the risk for major adverse cardiovascular events (MACE) and fracture prevention effects with denosumab versus bisphosphonates in dialysis-dependent patients. 

Read More